NOW VIRTUAL: Duke Debates Hematologic Malignancies (8.14.20)

blood

Update as of July 17, 2020: This event is now virtual

The 21st Annual Duke Debates conference on "Controversies in the Management of Hematologic Malignancies," presented by the Duke Cancer Network in collaboration with Duke Cancer Institute, will be held Friday, Aug. 14 in a virtual format.

The program chair and one of the Duke speakers is David Rizzieri, MD.

Duke speakers include Ahmed Galal, MD, Lindsay Rein, MD, Jie Wang, MD, Matthew McKinney, MD, Andrea Sitlinger, MD, Christopher Kelsey, MD, John J. Strouse, MD, PhD, and Nirmish Shah, MD.

Honored guest faculty speakers include Daniel DeAngelo, MD, PhD (DFCI), Ronan Swords, MD (AbbVie), Wendy Stock, MD (Chicago), Anjali Advani, MD (Cleveland Clinic), Josef Prchal, MD (Utah), Jonathon Cohen, MD, MS (Emory), and John Pagel, MD, PhD (SCI).

This educational program is directed toward oncologists, hematologists, pharmacists, pharmacy technicians, nurse practitioners, physician assistants, fellows, nurses and other health care professionals. The purpose of this conference is to educate oncologists, hematologists, and the healthcare team regarding evolving and contemporary standards of care for the optimal treatments of patients with hematologic malignancies.

Practical issues, current standards, and controversies in the management of these diseases will be discussed in debates, traditional lectures and tumor boards.

Topics include treatment management of AML in patients over 60 years old, AYA patients with BCR/ABL negative ALL, PV patients, patients with stage 1 mantle cell lymphoma, patients with relapsed mantle cell lymphoma, and CLL patients.

The use of CAR-T and other immunotherapies in the mangement of acute and late toxicities will also be debated, the role of the Molecular Tumor Board in hematologic malignancies, and the use of novel therapies in Sickle Cell disease will also be discussed.

DOWNLOAD PROGRAM

DOWNLOAD FLYER

REGISTER

Program

7:00-8:15 a.m. Vendor site open

8:00-8:05 a.m. Introductions

Featuring David Rizzieri, MD

8:05-8:15 a.m. Pre – conference questionnaire

8:15-9:00 a.m. Debate: All Patients Over the Age of 60 with AML Should Have Induction Therapy with Targeted Agents -(Ven/HMA; Glasdegib/HMA; or similar approach) Rather Than Standard 7 plus 3!

PRO: Daniel DeAngelo, MD, PhD (DFCI) vs. CON: Ronan Swords, MD (AbbVie)

9:00-9:45 a.m. Debate: PV Patients Can be Adequately Managed Through the Entire Course of Their Disease With Aspirin, Phlebotomy, Hydroxyurea and/or Interferon

PRO: Lindsay Rein, MD vs. CON: Josef Prchal, MD (Utah)

9:45-10:25 a.m. Debate: AYA Patients with BCR/ABL Negative ALL Should Receive a Pediatric Inspired Regimen and Reserve allo HSCT for Management of Relapse

PRO: Wendy Stock, MD (U. Chicago) vs. CON: Anjali Advani, MD (Cleveland Clinic)

10:25-11:05 a.m. Product Theater #1

11:05-11:45 a.m. Debate: Radiation Therapy Alone is the Preferred Management for Stage 1 Mantle Cell Lymphoma

PRO: Christopher Kelsey, MD vs. CON: Jonathon Cohen, MD, MS (Emory)

11:45 a.m.-12:30 p.m. Debate: Venetoclax should be used frontline in CLL before Ibrutinib

PRO: John Pagel, MD, PhD (SCI) vs. CON: Andrea Sitlinger, MD

12:30-1:10 p.m. Product Theater #2

1:10-1:50 p.m. Debate: Patients with relapsed mantle cell lymphoma should receive CAR-T therapy rather than traditional re-induction therapy and transplantation

PRO: Jie Wang, MD VS. CON: David Rizzieri, MD

1:50- 2:20 p.m. CAR-T and Immune Therapies Management of Acute and Late Toxicities - What the community provider needs to know

Featuring Ahmed Galal, MD

2:20-3:00 p.m. Product Theater #3

3:00-3:40 p.m. The Role of Molecular Tumor Board in Heme Malignancies and How Duke can support you!

Featuring Matthew McKinney, MD

3:40-4:20 p.m. Debate: Sickle Cell Topic: “Novel/New Therapies Are Worth It!”

PRO: John J. Strouse, MD, PhD vs. CON: Nirmish Shah, MD

4:20 p.m. Post Test Questions

4:45 p.m. Conference Evals and MOC directions

4:45 - 5:15 p.m. Vendor Site Open
 
Once you are registered, Beth Tanner, Duke Cancer Network, will be in contact with you if you need to make a payment. For more information Email Beth Tanner or call her at 919.681.9869 
*Note: If you are a speaker, please do NOT register. Your registration will be automatically be taken care of by Beth Tanner.